Journal of AIDS & Clinical Research

HIV Drug Resistance at Patients on HAART and Transmitted HIV Drug Resistance (tHIVDR) in Treatment Naive Patients in Belarus

Abstract

Vladimir Eremin, Elena Gasich, Sviataslau Sasinovich, Oleg Suetnov and Igor Kucherov

Of the 59 patients (adults) who have been identified to have a virus with a high level resistance to HAART drugs, in 38 (64.4%) patients mutation M184V/I was identified. In 27 (45.8%) patients (13 female and 14 male) K103N mutation was detected. In 20 (33.9%) patients (16 male and 4 female) we found G190G/S/A mutation. Of the 18 childrenpatients, born to HIV-infected mothers, in 15 (83.3%) cases (9 girls and 6 boys) we detected HIV resistance mutation M184V. In 10 (55.6%) and 2 (11.1%) cases mutations in position G190S and K103S were found, respectively. Of 82 samples collected from newly diagnosed HIV-infected antiretroviral naïve patients only 6 samples (7.3%) had other resistance mutations which can be classified as 'minor' or 'other' according to HIVDR database of Stanford University: L10V - PI minor mutation associated with resistance to most PIs when present with other mutations; L33F - PI minor mutation selected by FPV/r, DRV/r, LPV/r, ATV/r, and TPV/r, and contributes decreased susceptibility to these PIs; V118I - accessory mutation usually occurred with multiple TAMs and contributes some resistance to each of the NRTIs including 3TC and FTC; T74S is ‘other’ mutation associated with reduced NFV susceptibility; and V108I - accessory mutation, causes low-level resistance to NVP and EFV.